French Study Says Pfizer-Biontech Vaccine Less Effective against Indian Variant
A study by France’s Pasteur Institute found people who had received two doses of Pfizer saw a three-fold reduction in their antibodies against the B. 1.617 variant.
The Pfizer vaccine is slightly less effective but appears to still protect against the more transmissible Covid-19 variant first identified in India, according to a study by France’s Pasteur Institute.
“Despite slightly diminished efficacy, the Pfizer vaccine probably protects” against the Indian variant, according to laboratory test results, said Olivier Schwartz, the institute’s director and co-author of the study that was published on the BioRxiv website ahead of peer review.
The study sampled 28 health care workers in the city of Orleans. Sixteen of them had received two doses of the Pfizer vaccine, while 12 had received one dose of the AstraZeneca vaccine.
People who had received two doses of Pfizer saw a three-fold reduction in their antibodies against the Indian variant, B. 1.617, according to the study, but were still protected.
Since first emerging in late 2019 in China, the SARS-CoV-2 virus that causes Covid-19 has developed several variants, usually named for the places where it first appeared including the so-called South Africa and UK strains.
We need your support so Novinite.com can keep delivering news and information about Bulgaria! Thank you!
- » COVID-19 in Bulgaria: 429 New Cases
- » Bulgaria Enters Orange Covid Zone within Days, 462 New Covid-19 Cases
- » Germany Also Will Apply 3rd Dose Anti-covid Booster from September
- » COVID-19 in Bulgaria: 393 New Cases
- » Bulgaria is at the Beginning of Fourth COVID-19 Wave
- » COVID-19: More than One Million Vaccinated in Bulgaria